Supplementary




Figure S1 Kaplan-Meier survival curves for (A) OS and (B) CSS in IVA stage subgroups in EAC patients, stratified by chemotherapy and surgery.




Figure S2 Kaplan-Meier survival curves for(A) OS and (B) CSS in IVB stage subgroups in EAC patients, stratified by chemotherapy.

Table S1 Three-year and five-year OS rates in III/IV stage subgroups in EAC patients

Stage	Subgroup	3-year		5-year	
		Survival (%)	95% CI	Survival (%)	95% CI
III	T2N1M0	44.1	39.4–49.4	29	24.7–34.1
	T3N0-1M0	34.6	32.3-37.0	23.6	21.5–25.9
	T4aN0-1M0	25.1	20.1–31.3	18.4	14.0–24.2
IVA	T1N2-3M0	39.5	22.4-69.9	26.4	11.8–58.8
	T2N2-3M0	30	22.6–39.9	20.2	13.9–29.5
	T3N2-3M0	25	21.9–28.6	17.2	14.4–20.4
	T4aN2-3M0	16.8	9.0-31.2	10.1	4.3-23.7
	T4bN0-3M0	16.1	9.9–26.2	8.5	4.1–17.4
IVB	T1N0-3M1	5.4	2.4–12.1	2.9	0.9–9.7
	T2N0-3M1	14.3	9.5–21.6	10	5.9–16.8
	T3N0-3M1	7.7	5.9–10.1	3.6	2.4-5.6
	T4aN0-3M1	5.3	3.1-9.1	3.6	1.8-6.9
	T4bN0-3M1	2.8	0.9-8.2	0.9	0.1–6.4

 $\textbf{Table S2} \ \textbf{3-year and 5-year CSS rates in III/IV stage subgroups in EAC patients}$

Stage	Subgroup	3-year		5-year	
		Survival (%)	95% CI	Survival (%)	95% CI
III	T2N1M0	51.2	46.2–56.7	37.4	32.5–43.2
	T3N0-1M0	39.0	36.6–41.6	28.5	26.2–31.1
	T4aN0-1M0	28.8	23.4–35.4	21.6	16.6–28.0
IVA	T1N2-3M0	47.8	29.6–77.0	39.8	21.9–72.3
	T2N2-3M0	37.4	29.0-48.2	27.1	19.2–38.1
	T3N2-3M0	27.6	24.3–31.4	20.1	17.0–23.6
	T4aN2-3M0	18.4	10.0–33.9	13.8	6.6–28.7
	T4bN0-3M0	17.6	11.0–28.4	10.2	5.1–20.2
IVB	T1N0-3M1	6.3	2.9-13.9	3.4	1.0–11.3
	T2N0-3M1	16.2	10.9–24.0	11.3	6.8–18.8
	T3N0-3M1	9.2	7.1–11.9	4.6	3.1-6.9
	T4aN0-3M1	5.9	3.5–10.0	4.4	2.4-8.2
	T4bN0-3M1	3.6	1.3–10.2	1.2	0.2-8.1